9,522 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Aigen Investment Management LP

Key Points

• Aigen Investment Management LP has acquired 9,522 shares of TG Therapeutics, Inc. (NASDAQ:TGTX), valued at approximately $375,000, during the first quarter.
• Director Yann Echelard sold 10,000 shares at an average price of $36.94, reducing his ownership by 4.19%, while retaining 228,816 shares valued at around $8.45 million.
• TG Therapeutics reported a 92.1% increase in revenue year-over-year, with an EPS of $0.17 for the latest quarter, falling short of analysts’ expectations by $0.15.

Aigen Investment Management LP bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 9,522 shares of the biopharmaceutical company's stock, valued at approximately $375,000.

Several other large investors have also recently bought and sold shares of the company. Entropy Technologies LP raised its position in TG Therapeutics by 251.5% in the first quarter. Entropy Technologies LP now owns 30,859 shares of the biopharmaceutical company's stock valued at $1,217,000 after purchasing an additional 22,079 shares during the last quarter. Invesco Ltd. raised its position in TG Therapeutics by 30.2% in the first quarter. Invesco Ltd. now owns 1,210,842 shares of the biopharmaceutical company's stock valued at $47,744,000 after purchasing an additional 281,099 shares during the last quarter. Pandora Wealth Inc. bought a new position in TG Therapeutics in the first quarter valued at about $3,300,000. Citigroup Inc. raised its position in TG Therapeutics by 0.6% in the first quarter. Citigroup Inc. now owns 349,104 shares of the biopharmaceutical company's stock valued at $13,765,000 after purchasing an additional 1,927 shares during the last quarter. Finally, Deutsche Bank AG raised its position in TG Therapeutics by 1.1% in the first quarter. Deutsche Bank AG now owns 148,705 shares of the biopharmaceutical company's stock valued at $5,863,000 after purchasing an additional 1,685 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.64% of the company's stock.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a research report on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $46.25.

TG Therapeutics Trading Up 1.1%

Shares of TGTX stock traded up $0.31 on Friday, hitting $28.08. The company had a trading volume of 1,811,717 shares, compared to its average volume of 2,818,288. The firm has a market cap of $4.46 billion, a P/E ratio of 75.89 and a beta of 1.95. The stock's 50-day moving average is $35.07 and its two-hundred day moving average is $35.85. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.04 and a current ratio of 3.86. TG Therapeutics, Inc. has a twelve month low of $20.81 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The company had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The company's quarterly revenue was up 92.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 EPS. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.